IN THE CLAIMS

Please cancel claims 1-10 and 15-16 without prejudice.

Please add claim 21, and amend claims 11-14 and 17-19 as follows:

1-10. (Canceled)

11. (Currently amended) A phosphoramidate compound formed from an hydroxy functional or amino functional drug eompound of having the general formula Drug-ZH, said prodrug being a compound of having the formula:

$$R_rCH_2OP(O)(Z-Drug)NR(CH_2)_nX$$

wherein:

R is C_1 - C_4 alkyl or - $(CH_2)_nX$;

n is 4 or 5;

Z is O or N;

X is an electrophilic group capable of being nucleophilically displaced from its bonded carbon atom; and

halo is chloro, bromo or iodo; and

the group R_rCH₂- is a biologically labile ester forming group.

- 12. (Currently amended) The <u>prodrug compound</u> of claim 11 wherein the drug is an amino acid, or a biologically active peptide, or <u>a peptidomimetic</u>.
- 13. (Currently amended) The method compound of claim 12 wherein Drug-ZH is a peptidomimetic of having the formula:

$$HZ - (CH_2)_q[CHB]_kC(O)NHCH(CH_3) - O$$

wherein Z is O or N;

q and k are independently 1 or 0; and

B is H, amino, protected amino, or C₁-C₄ alkanoylamino.

14. (Currently amended) The <u>prodrug compound</u> of claim 11 wherein the drug is a biologically active nucleotide analog.

15-16. (Canceled)

17. (Currently amended) A pharmaceutical composition comprising a phosphoramidate compound formed from a-an hydroxy functional or amino functional drug compound of having the general formula Drug-ZH, said prodrug being a compound of having the formula:

$$R_rCH_2OP(O)(Z-Drug)NR(CH_2)_nX$$

wherein

R is C_1 - C_4 alkyl or - $(CH_2)_nX$;

n is 4 or 5;

Z is O or N;

X is an electrophilic group capable of being nucleophilically displaced from its bonded carbon atom; and

halo is chloro, bromo or iodo;

the group R_rCH₂- is a biologically labile ester forming group; and a pharmaceutically acceptable carrier therefor.

- 18. (Currently amended) The pharmaceutical <u>composition</u> of claim 17 wherein Drug-ZH is an amino acid, or a biologically active peptide, or <u>a peptidomimetic</u>.
- 19. (Currently amended) The pharmaceutical composition of claim 18 wherein Drug-ZH is a peptidomimetic of having the formula:

$$\mathsf{HZ} - (\mathsf{CH_2})_{\mathsf{q}} [\mathsf{CHB}]_{\mathsf{k}} \mathsf{C}(\mathsf{O}) \mathsf{NHCH}(\mathsf{CH_3}) - \mathsf{O}$$

wherein Z is O or N;

q and k are independently 1 or 0; and

B is H, amino, protected amino, or C₁-C₄ alkanoylamino.

- 20. (Original) The pharmaceutical composition of claim 17 wherein Drug-ZH is a nucleotide analog.
- 21. (New) The compound of claim 11 wherein R is methyl; n is 4; X is chloro; the group R_rCH_2 is a radical having the formula:

$$H_2C$$
 O ; and

Drug-ZH is a nucleotide analog having the formula:

wherein Z is oxygen.